Metronomic Chemotherapy in Advanced Gastric Cancer

Status unconfirmed · Phase 2

Conditions studied: Metastatic Gastric Cancer, Locally Advanced Gastric Cancer

In brief

phase II study of weekly metronomic chemotherapy using weekly Paclitaxel, Oxaliplatin, Leucovorin and 5-FU (POLF) in patients with advanced gastric cancer

Key facts

Study ID

NCT02855788

Run by

Huashan Hospital

People needed

40

Starts

2015-05-01

Expected to finish

2018-10-01

Last updated by the study team

2016-08-04

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• pathologically confirmed gastric cancer AJCC stage III or IV
• measurable disease based on CT or endoscopy exam
• non-surgical candidates or patients who declined surgery
• non-radiation candidates or patients who declined radiation
• patients who are able to sign informed consent
• patients who are 2 weeks out and recovered from surgery
• patients who have completed radiation to relieve obstructive symptoms
• patient who previously received Oxaliplatin and 5-FU in other MTD regimens
• adequate marrow function: neutrophil >1000/ul, Hgb >10g/dl, Plt>50,000

You may not qualify if…

• allergic to any of the drugs involved
• concurrent malignancies
• severe co-morbidities of heart, lungs, kidneys and bone marrow
• severe psychological disorder
• severe malnutrition
• difficult to heal or unhealed wound
• ECOG performance status equal or over 3
• uncontrolled complications from the malignancy
• uncontrolled CNS metastasis
• peripheral neuropathy grade 3 or above
• pregnancy or breast feeding

Where it is running

• Huashan Hospital — Shanghai, Shanghai Municipality, China (enrolling)
• Seattle Integrative Cancer Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.